Local Coverage Determination (LCD):
MolDX: DecisionDx-Melanoma (L37750)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01111 - MAC A</td>
<td>J - E</td>
<td>California - Entire State</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01112 - MAC B</td>
<td>J - E</td>
<td>California - Northern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01182 - MAC B</td>
<td>J - E</td>
<td>California - Southern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01211 - MAC A</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guam</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hawaii</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01212 - MAC B</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guam</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hawaii</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01311 - MAC A</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01312 - MAC B</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01911 - MAC A</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>California - Entire State</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guam</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hawaii</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nevada</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Northern Mariana Islands</td>
</tr>
</tbody>
</table>

## Document Information

**LCD ID**

**Original Effective Date**

Created on 02/06/2020. Page 1 of 11
**LCD Title**
MolDX: DecisionDX-Melanoma

**Proposed LCD in Comment Period**
N/A

**Source Proposed LCD**
DL37750

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**
CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

**CMS National Coverage Policy**
Title XVIII of the Social Security Act, §1862(a)(1)(A). Allows coverage and payment for only those services that are...
considered to be reasonable and necessary.

Title XVIII of the Social Security Act, §1833(e). Prohibits Medicare payment for any claim which lacks the necessary information to process the claim.


CMS On-Line Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, §§80.0, 80.1.1, 80.2. Clinical Laboratory services.

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) "Reporting ICD Diagnosis and Procedure Codes".

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

The DecisionDx-Melanoma test is covered only when the following clinical conditions are met:

- Patients diagnosed with clinical stage, sentinel lymph node biopsy (SLNB) eligible, T1 and T2 cutaneous melanoma tumors (as defined in AJCC Staging Manual v8, 2017) with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy. (Per current NCCN and ASCO guidelines, SLNB eligible patients are defined as:
  - Patients with T1a tumors:
    - in whom there is significant uncertainty about the adequacy of microstaging (positive deep margin), or
    - with Breslow depth <0.8 mm and with other adverse features (e.g. very high mitotic index \[\geq 2/mm^2\], lymphovascular invasion, or a combination of these factors)
  - Patients with T1b tumors (\(\geq 0.8 \text{ mm or}< 0.8 \text{ mm with ulceration})
  - Patients with T2 tumors

Claims for DecisionDx-Melanoma testing will be denied when testing does not meet all of the above criteria.

Summary of Evidence

Background

Cutaneous melanoma (CM) is increasing in incidence in the U.S., with more than 87,000 cases expected to be diagnosed in 2017 and nearly 10,000 deaths each year [1]. Of these, more than 70,000 patients are diagnosed with Stage I or II disease (localized) as determined by the American Joint Committee on Cancer (AJCC) staging system [1]. Patients with early stage melanoma (i.e. AJCC Stage I-II) are regarded as good-prognosis based on population-based risk estimates. However, due to the greater number of individuals within these earlier stages, more than twice as many people diagnosed with early stage disease will ultimately die of melanoma compared to those diagnosed with Stage III melanoma [2].
The DecisionDx-Melanoma test is a 31-gene expression profile (GEP) that determines a CM patient’s risk for metastatic disease [3-6]. The test classifies patients as having a tumor with low (Class 1) or high (Class 2) risk for developing metastasis within 5 years of diagnosis. Patients with a Class 1 tumor profile also have a low likelihood of being sentinel lymph node (SLN) positive. Thus, the individualized risk profile result of this test can be used to guide use of SLNB in the context of patient-specific management plans.

Per current national guidelines, a SLNB procedure is considered for all patients with melanoma pathologic Stage T1b and above, as well as those patients with T1a tumors in whom there is significant uncertainty about the adequacy of microstaging [7, 8]. Patients with a positive SLN are at substantially increased risk for distant metastatic disease and death [2], however, the procedure only provides prognostic information, and the MSLT-II study showed no survival benefit associated with completion lymphadenectomy in SLN positive patients [9]. Currently, the identification of SLN positive patients helps identify Stage III patients who can potentially benefit from targeted and immunotherapeutic agents in the adjuvant setting [10-13]. The procedure can be associated with complications in a substantial proportion of patients such as pain, seromas, nerve damage and edema, and requires a large team of dedicated personnel, including nuclear medicine physicians, surgeons, and pathologists [14-16]. It has been estimated that the cost of a SLNB can be 10 times that of a wide excision alone, and the cost per life saved in a patient population with low prevalence of positive SLN can approach 1 million dollars [17]. Overall, the likelihood of a positive SLN after the SLNB procedure is 16% [2, 18], but this is variable for specific populations [18-21]. Elderly patients account for a substantial proportion of CM patients, and 60% of melanoma-related deaths occur in patients ≥65 years-old. While older age is associated with a poor prognosis, fewer elderly patients are SLN positive [19-23], which indicates that the prognostic value of SLNB is limited in this population [24, 25].

In general, a 5% likelihood for a positive SLN is recommended as a threshold for performing this procedure in a patient population [18]. Analysis of Castle’s retrospective cohort (n=782) identified that DecisionDx-Melanoma Class 1A patients (probability score <0.5) with tumors who had a Breslow thickness (BT) of ≤2.0 mm (AJCC T1-T2) achieved a positive SLNB rate below 5% [26]. To validate this clinical use of the Class 1A cut-point for the DecisionDx-Melanoma test, two contemporary, multi-center, prospective study cohorts were tested: 584 patient cohort from two published prospective studies (overall 14% SLN positive rate) [6, 27] and a 837 patient cohort from prospectively tested patients at 5 large academic institutions (overall 12% SLN positive rate) [26]. The rate of SLN positivity in both prospective study cohorts aligns with the SLN positivity rate in the general population of melanoma patients who have undergone SLNB. The results show that in patients from the Medicare-eligible population (65 years old and over) who had a SLNB performed, those patients who had a DecisionDx-Melanoma Class 1A T1 or T2 tumor, have a 98.4% probability of being SLN negative. Thus, in this patient group, the DecisionDx-Melanoma test achieves a NPV that is comparable to other molecular tests used to guide surgical management decisions [28-31].

Analysis of the two prospective cohorts combined (n=1,421 patients) shows that SLN positivity rates are enriched from 12.8% using current SLNB criteria to 18.6% in those patients who would undergo the SLN biopsy procedure (T1/T2 with a Class 2 DecisionDx-Melanoma test result and T3/T4 patients). The rate of SLN positivity in the 65 years and older population from Castle’s prospective cohort (n=629) is 14.6% of Class 1A patients and 11.9% for Class 2B patients. SLN positivity rates for T3 tumors is 8.7% for Class 1A compared to 18% for Class 1B-2B; for T4 tumors it is 17% and 17% respectively. Importantly, the 5-year melanoma specific survival (MSS) rate for T1/T2 Class 1 patients remains favorable; with 99% MSS, comparable to that observed in T1a tumors and for which current guidelines do not recommend SLNB [7, 32, 33]. Furthermore, T1/T2 Class 1 patients show 5-year overall survival (OS) of 97% and distant metastasis free survival (DMFS) of 93% [33]. The MSLT-II study demonstrated that a delay in lymph node dissection does not adversely affect survival, thus clinical follow up of Class 1 patients and lymphadenectomy for those few who develop clinically detectable nodal disease should achieve similar outcomes to those who currently undergo a planned SLNB [9]. Thus, the test identifies a patient population with <5% likelihood of a positive SLN and high survival rates and therefore has utility in guiding SLNB decisions in patients 65 years-old and over with T1-T2 CM tumors. In this population, the test could potentially reduce the rate of SLNB by up to 78% while still maintaining a MSS survival rate of 99% in those patients with low-risk tumor biology who can safely avoid the procedure.
Clinical validation of DecisionDx-Melanoma as a prognostic test for CM patients was performed in three multicenter, prospectively designed archival tissue studies including 782 patients [3-5]. These studies have shown that the test accurately predicts risk for local/regional recurrence, distant metastasis, melanoma-related mortality, and all-cause mortality independent of clinicopathologic factors used in staging and that the test shows improved sensitivity and negative predictive value (NPV) for recurrence-free (RFS), distant metastasis-free (DMFS), melanoma-specific (MSS) and overall (OS) survival individually or in conjunction with established clinicopathologic factors. Three prospective, independent studies (n= 510) and an interim analysis of two prospective registries (n=322) have confirmed the prognostic accuracy of DecisionDx-Melanoma [6, 34-36].

The DecisionDx-Melanoma test may improve net health outcomes by accurately identifying patients who are at risk of developing metastatic disease and would otherwise go undetected, as well as patients with a low likelihood of having a positive SLN. Net health outcomes are improved for low risk Class 1 patients who can consider avoiding SLNB and associated surgical and anesthesia risk (T1-T2 patients), as well as intensive follow up and exposure to radiation from imaging procedures, and for high risk Class 2 patients by improved guidance to perform SLNB.

Summary of Analytical and Clinical Performance

General

Intended Use

The DecisionDx-Melanoma test is intended for SLNB-eligible T1 and T2 cutaneous melanoma tumors (as defined in AJCC Staging Manual v8, 2017) with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy.

Validated Specimen Type(s)

Formalin-fixed, paraffin-embedded (FFPE) specimens of the primary tumor.

Analytical Performance [37]

<table>
<thead>
<tr>
<th>Description</th>
<th>Results (with 95% Confidence Intervals if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeatability (within run precision)</td>
<td>Binary Classification (Class 1 / Class 2): 100% (94-100%) Subclassification: (Class 1A/1B; Class 2A/2B): 98% (91-100%)</td>
</tr>
<tr>
<td>Intermediate precision (between run precision)</td>
<td></td>
</tr>
<tr>
<td>Inter-operator/instrument:</td>
<td>Binary Classification (Class 1 / Class 2): 95% (77-100.0%) Subclassification: (Class 1A/1B; Class 2A/2B): 95% (77-100%)</td>
</tr>
<tr>
<td>Inter-assay:</td>
<td>Binary Classification (Class 1 / Class 2): 99% (96-100.0%) Subclassification: (Class 1A/1B; Class 2A/2B): 92% (87-96%)</td>
</tr>
<tr>
<td>Reproducibility (between sites)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Minimum input RNA quantity</td>
<td>5 ng RNA</td>
</tr>
<tr>
<td>Minimum tumor content (for FFPE specimens)</td>
<td>40% by histomorphology</td>
</tr>
<tr>
<td>Limit of blank (LOB)</td>
<td>CT undetermined for blank</td>
</tr>
<tr>
<td>Limit of detection (LOD)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Limits of quantitation (LOQ)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Linearity</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Interfering substances</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Specimen stability, primary</td>
<td>FFPE x 4 years at RT per literature and up to 16 years in outcome specimens</td>
</tr>
</tbody>
</table>

Created on 02/06/2020. Page 5 of 11
Specimen stability, intermediate (extracted RNA)
Specimen stability, intermediate (cDNA)

96 hours when stored at -80°C per SOP
96 hours when stored at 4°C per SOP 30 days when stored at -20°C per SOP

Applied Biosystems TaqMan® Low Density Array, -20°C x 24 months (lab) Applied Biosystems TaqMan® Open Array, -20°C x 12 months (lab) Applied Biosystems High-Capacity cDNA Reverse Transcription Kit , -20 °C x 8 months / 3 months (lab)

Critical reagent closed/shelf-life stability
(manufacturer’s recommendations/lab validated)

Applied Biosystems TaqMan® PreAmp Master Mix Kit, 4°C x 9 months / 3 months (lab)

Critical reagent open/in use stability
Per lab validation or manufacturer’s specifications

Using Clopper-Pearson method

Since the gene expression profile is based on ratios of gene to controls, rather than an absolute value, the effect of an interfering agent is expected to affect all genes equally and result in failed amplification.

Clinical Performance: Utility

Data below shows that using the DecisionDx-Melanoma test for SLNB guidance in T1/T2 as defined by AJCC v8 identifies a patient population with <5% likelihood of a positive SLN with high rates of MSS, OS and DMFS, OS and therefore may have utility in guiding SLNB decisions in Medicare patients. In this population, the test will reduce the rate of SLNB by up to 52% while still maintaining a MSS survival rate of 99% in those patients with low-risk tumor biology who can safely avoid the procedure.

Summary of DecisionDx-Melanoma performance in SLNB guidance in T1/T2 melanoma patients ≥65 years old, eligible for SLNB biopsy

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Overall N</th>
<th>NPV</th>
<th>SLN+ Rate T1/T2 Patients</th>
<th>SLN+ Rate T1/T2 Class 1B-2B Patients</th>
<th>SLN+ Rate All Patients Directed to SLNB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castle Prospective Studies(^c)</td>
<td>193</td>
<td>0.99 (0.93-1)</td>
<td>3.33%</td>
<td>7.32%</td>
<td>15.79%</td>
</tr>
<tr>
<td>Independent Validation Cohort(^d)</td>
<td>335</td>
<td>0.97 (0.93-0.99)</td>
<td>5.29%</td>
<td>10.00%</td>
<td>12.23%</td>
</tr>
<tr>
<td>Combined</td>
<td>528</td>
<td>0.98 (0.95-0.99)</td>
<td>4.61%</td>
<td>9.09%</td>
<td>13.58%</td>
</tr>
</tbody>
</table>

NPV = Negative Predictive Value in for SLN positivity in SLNB eligible T1/T2 patients with Class 1A DecisionDx-Melanoma test result

\(^a\)Patients eligible for SLNB per NCCN guidelines or had a SLNB procedure performed

\(^b\)SLNB positive rate in all patients undergoing SLNB after guidance with test (T1/T2 Class 1B-2B and T3/T4)

\(^c\)Data from two contemporary, prospective, multicenter studies (total n=584) [6, 27]

\(^d\)Data from independent cohort from 5 academic centers (total n=837) [26]
Expected survival outcomes in T1/T2 patients who avoid or undergo SLNB based on DecisionDx-Melanoma class result

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>MSS</th>
<th>OS</th>
<th>DMFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1/T2 Class 1 (No SLNB)</td>
<td>99.3%</td>
<td>97.2%</td>
<td>93.4%</td>
</tr>
<tr>
<td>T1/T2 Class 2 SLNB Negative</td>
<td>95.3%</td>
<td>95.3%</td>
<td>86.3%</td>
</tr>
<tr>
<td>T1/T2 Class 2 SLNB Positive</td>
<td>73.8%</td>
<td>52.4%</td>
<td>52.5%</td>
</tr>
</tbody>
</table>

Data from three retrospective, multicenter cohorts (N=690)
Median follow up time of cohort = 6.5 yr [3-5, 26]
Note: Limited data for Class 1 T1/T2 patients who were found to be SLNB positive under current guidelines showed MSS, OS and DMFS rates of 100%, 90.7 and 75.7%.

Clinical Performance: Validity

Summary of event rates in DecisionDx-Melanoma clinical validity studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population</th>
<th>Non-censored recurrence rate (95% CI)</th>
<th>Non-censored distant metastasis rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerami et al., 2015 CCRa [3]</td>
<td>Archival, prospective design</td>
<td>Stage I-II, n=78; mf/u: 5.7 years</td>
<td>5.8% (1.2-16%) 3/52</td>
<td>37% (21-56%) 2/14</td>
</tr>
<tr>
<td>Gerami et al., 2015 JAADb [4]</td>
<td>Archival, prospective design</td>
<td>SLN-eligible, Stage I-III, n=217; mf/u: 4.2 years</td>
<td>21% (13-32%) 16/7665% 56-72% 91/141 18% (10-32%) 36/201 14/71</td>
<td></td>
</tr>
<tr>
<td>Zager et al., 2017 [5]</td>
<td>Archival, prospective design</td>
<td>Stage I-III, n=523; mf/u: 6.1 years</td>
<td>13% (9.8-18%) 42/314</td>
<td>48% (41-55%) 100/209 27% (17-38%) 71/261 9% (6-12%) 28/31</td>
</tr>
<tr>
<td>Greenhaw et al., 2017 [34]</td>
<td>Consecutively tested, single center</td>
<td>Stage I-II, n=256; mean f/u: 1.9 years</td>
<td>1.4% (0.3-4%) 3/214</td>
<td>24% (12-39%) 10/42 4% (0.1-7%) 2/50</td>
</tr>
<tr>
<td>Hsueh et al., 2017 [35]</td>
<td>Prospective, single center</td>
<td>Stage I-III, n=159; mf/u: 2.1 years</td>
<td>2.6% (0.53-7.3%) 3/117</td>
<td>45% (30-61%) 19/42 2% (0.1-6%) 2/40</td>
</tr>
<tr>
<td>Hsueh et al., 2017 [6]</td>
<td>Prospective registries</td>
<td>Stage I-III, n=322; mf/u: 1.5 years</td>
<td>2% (0.66-4.6%) 5/248</td>
<td>27% (17-38%) 20/74 1% (0.1-6%) 2/40</td>
</tr>
<tr>
<td>Renzetti et al., 2017 [36]</td>
<td>Consecutively tested, single center</td>
<td>Stage I-III, n=95; mf/u: 0.9 years</td>
<td>4.9% (0.6-17%) 2/41</td>
<td>24.1% (13-38%) 13/54 2.4% (0.06-12%) 1/41</td>
</tr>
</tbody>
</table>

mf/u = median follow-up
Confidence intervals calculated by the Coppler-Pearson method

aRecurrence in Gerami et al., 2015 CCR included sentinel lymph node positivity as an event, while all other studies did not. Therefore, for this study, only Stage I-II patients are included.
bPatients in this study were eligible for SLNB so they include Stage I-II patients at a higher risk of metastasis, thus event rates in Class 1 is expected to be higher than in other studies.

Summary of survival outcomes in DecisionDX-Melanoma clinical validity studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population</th>
<th>Recurrence-free Survival (RFS) rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerami et al., 2015 CCRa [3]</td>
<td>Archival, prospective design</td>
<td>Stage I-II, n=78; mf/u: 5.7 years</td>
<td>98% (93-100%)c 37% (21-56%)</td>
</tr>
</tbody>
</table>

Created on 02/06/2020. Page 7 of 11
Gerami et al., 2015
Archival, prospective design
SLN-eligible, Stage I-III, n=217; mf/u: 4.2 years
79% (70-90%)\(^c\)  33% (26-43%)

Zager et al., 2017 [5]
Archival, prospective design
Stage I-III, n=523 mf/u: 6.1 years
88% (85-92%)\(^c\)  52% (46-60%)

Greenhaw et al., 2017 [34]
Consecutively tested, single center
Stage I-II, n=256; mean f/u: 1.9 years
98% (95-100%)\(^d\)  74% (59-93%)

Hsueh et al., 2017 [35]
Prospective, single center
Stage I-III, n=159 mf/u: 2.1 years
97% (95-100%)\(^e\)  54% (41-72%)

Hsueh et al., 2017 [6]
Prospective registries
Stage I-III, n=322 mf/u: 1.5 years
97% (95-100%)\(^f\)  77% (67-88%)

mf/u = median follow-up
Survival rates and confidence intervals calculated by Kaplan-Meier method
\(^a\)Recurrence in Gerami et al., 2015 CCR included sentinel lymph node positivity as an event, while all other studies did not. Therefore, for this study, only Stage I-II patients are included.
\(^b\)Patients in this study were eligible for SLNB so they include Stage I-II patients at a higher risk of metastasis, thus event rates in Class 1 is expected to be higher than in other studies
\(^c\)5-year survival outcomes
\(^d\)3-year survival outcomes
\(^e\)2-year survival outcomes
\(^f\)1.5-year survival outcomes

Analysis of Evidence
(Rationale for Determination)

Level of Evidence
Quality of evidence – Moderate
Strength of evidence – Low
Weight of evidence - Low

This contractor will cover the DecisionDx-Melanoma test for patients diagnosed with SLNB eligible T1b and T2 tumor who are being considered for SLNB. The DecisionDx-Melanoma assay should not be ordered if a patient and his/her physician do not intend to act upon the test result. Continued coverage is dependent on the publication and/or presentation of additional clinical utility data demonstrating the impact of the test’s use on patient management decisions with (1) 95% or greater DMFS and MSS at 3 years in patients directed to no SLNB by the test compared to standard of care, and (2) evidence of higher SLNB positivity in patients selected for this procedure by the test compared to standard of care.

General Information

Created on 02/06/2020. Page 8 of 11


Revision History Information

<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td>R2</td>
<td>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.</td>
<td>• Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)</td>
</tr>
</tbody>
</table>

Created on 02/06/2020. Page 10 of 11
<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td>R1</td>
<td>As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</td>
<td>- Revisions Due To Code Removal</td>
</tr>
</tbody>
</table>

**Associated Documents**

**Attachments**

N/A

**Related Local Coverage Documents**

Article(s)
A57417 - Billing and Coding: MolDX: DecisionDx-Melanoma
A56230 - Response to Comments: MolDX: DecisionDx-Melanoma

LCD(s)
DL37750
- (MCD Archive Site)

**Related National Coverage Documents**

N/A

**Public Version(s)**

Updated on 01/29/2020 with effective dates 11/01/2019 - N/A
Updated on 10/08/2019 with effective dates 11/01/2019 - N/A
Updated on 12/14/2018 with effective dates 02/10/2019 - N/A

**Keywords**

N/A